The U.S. Patent and Trademark Office (USPTO) today officially withdrew its controversial proposed rule on terminal disclaimer practice. The withdrawal was expected, with panelists at IPWatchdog’s Life ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

Erroneous attempts to blame patents for high drug prices is continuing unabated, with the Administration and courts making it harder to obtain and keep sufficient patent protection for even ...

"'In re Cellect' and the USPTO’s proposed rule have the potential to fundamentally affect patent practice, particularly in the realm of terminal disclaimers filed to overcome ODP rejections," write ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

To ring the register, a pharmaceutical company may create a patent thicket, which involves filing dozens of patents that, in some cases, add little value to their medicines but extend precious ...

A new USPTO proposal could encourage counsel to advise their patent owner clients to file fewer terminal disclaimers, say sources. The USPTO released a notice of proposed rulemaking on May 9 that ...

To ring the register, a pharmaceutical company may create a patent thicket, which involves filing dozens of patents that, in some cases, add little value to their medicines but extend precious ...